Katrine B. Melhus

Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate

Jostein Dahle, Jørgen Borrebæk, Thora J. Jónasdóttir et al. · Blood · 2007 · 80 citations · Full text

Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy

Jostein Dahle, Jørgen Borrebæk, Katrine B. Melhus et al. · Nuclear Medicine and Biology · 2006 · 56 citations

Radiation Medicine, Initial Evaluation, Radiation Therapy +5

Preparation of TH ²²⁷ -Labeled Radioimmunoconjugates, Assessment of Serum Stability and Antigen Binding Ability

Roy H. Larsen, Jostein Dahle, Katrine B. Melhus et al. · Cancer Biotherapy and Radiopharmaceuticals · 2007 · 48 citations

Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.

Jostein Dahle, Ada H. V. Repetto‐Llamazares, Camilla Mollatt et al. · PubMed · 2013 · 45 citations

Immunology, Pathology, Immunotherapy +16

In Vitro Cytotoxicity of Low-Dose-Rate Radioimmunotherapy by the Alpha-Emitting Radioimmunoconjugate Thorium-227–DOTA–Rituximab

Jostein Dahle, Cecilie Krogh, Katrine B. Melhus et al. · International Journal of Radiation Oncology*Biology*Physics · 2009 · 22 citations

Radiation Medicine, Engineering, Radiation Therapy +15